Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080369 | 0.99 | REN (0.46) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3082440 | 0.96 | REN (0.43) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3078793 | 0.95 | REN (0.44) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3064999 | 0.94 | REN (0.46) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3259416 | 0.92 | REN (0.42) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3073886 | 0.91 | REN (0.43) | RENCYP3A4CHRM1 | |
| SCHEMBL3418652 | 0.91 | REN (0.43) | RENCYP3A4CHRM1DRD2DRD4 | |
| SCHEMBL3205328 | 0.91 | REN (0.40) | RENCYP3A4CHRM1 | |
| SCHEMBL3072930 | 0.90 | REN (0.56) | RENCYP3A4 | |
| SCHEMBL3415061 | 0.90 | REN (0.45) | RENCYP3A4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP3A4 29/4885CHRM1 1675/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885CYP3A4 29/4885CHRM1 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.